Ayumu Okumura

Ayumu Okumura

Auto-generated profile, based on publicly available information

Ayumu Okumura

Division of Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
TTTomomi Tadokoro
Tomomi Tadokoro
SMSoichiro Murata
Soichiro Murata
MKMimoko Kato
Mimoko Kato
YUYasuharu Ueno
Yasuharu Ueno
TTTomonori Tsuchida
Tomonori Tsuchida
HTHideki Taniguchi
Hideki Taniguchi
Donor organ shortages for transplantation remain a serious global concern, and alternative treatment is in high demand. Fetal cells and tissues have considerable therapeutic potential as, for example, organoid technology that uses human induced pluripotent stem cells (hiPSCs) to generate unlimited human fetal-like cells and tissues. We previously reported the in vivo vascularization of early fetal liver–like hiPSC-derived liver buds (LBs) and subsquent improved survival of recipient mice with subacute liver failure. Here, we show hiPSC–liver organoids (LOs) that recapitulate midgestational fetal liver promote de novo liver generation when grafted onto the surface of host livers in chemical fibrosis models, thereby recovering liver function. We found that fetal liver, a hematopoietic tissue, highly expressed macrophage-recruiting factors and antifibrotic M2 macrophage polarization factors compared with the adult liver, resulting in fibrosis reduction because of CD163 + M2-macrophage polarization. Next, we created midgestational fetal liver–like hiPSC-LOs by fusion of hiPSC-LBs to induce static cell-cell interactions and found that these contained complex structures such as hepatocytes, vasculature, and bile ducts after transplantation. This fusion allowed the generation of a large human tissue suitable for transplantation into immunodeficient rodent models of liver fibrosis. hiPSC-LOs showed superior liver function compared with hiPSC-LBs and improved survival and liver function upon transplantation. In addition, hiPSC-LO transplantation ameliorated chemically induced liver fibrosis, a symptom of liver cirrhosis that leads to organ dysfunction, through immunomodulatory effects, particularly on CD163 + phagocytic M2-macrophage polarization. Together, our results suggest hiPSC-LO transplantation as a promising therapeutic option for liver fibrosis.

28 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ECErica Carolina
Erica Carolina
YKYoshiki Kuse
Yoshiki Kuse
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
TTTomomi Tadokoro
Tomomi Tadokoro
HTHideki Taniguchi
Hideki Taniguchi
In fetal development, tissue interaction such as the interplay between blood vessel (BV) and epithelial tissue is crucial for organogenesis. Here we recapitulate the spatial arrangement between liver epithelial tissue and the portal vein to observe the formation of intrahepatic bile ducts (BDs) from human induced pluripotent stem cells (hiPSC). We co-culture hiPSC-liver progenitors on the artificial BV consisting of immature smooth muscle cells and endothelial cells, both derived from hiPSCs. After 3 weeks, liver progenitors within hiPSC-BV-incorporated liver organoids (BVLO) differentiate to cholangiocytes and acquire epithelial characteristics, including intercellular junctions, microvilli on the apical membrane, and secretory functions. Furthermore, liver surface transplanted-BVLO temporarily attenuates cholestatic injury symptoms. Single cell RNA sequence analysis suggests that BD interact with the BV in BVLO through TGFβ and Notch pathways. Knocking out JAG1 in hiPSC-BV significantly attenuates bile duct formation, highlighting BVLO potential as a model for Alagille syndrome, a congenital biliary disease. Overall, we develop a novel 3D co-culture method that successfully establishes functional human BDs by emulating liver epithelial-BV interaction.

19 September 2024 in Biomaterials
Verified
Journal Article
Open access
STShunsuke Tabe
Shunsuke Tabe
KTKenta Takeuchi
Kenta Takeuchi
KAKenji Aoshima
Kenji Aoshima
AOAyumu Okumura
Ayumu Okumura
YYYuya Yamamoto
Yuya Yamamoto
HTHideki Taniguchi
Hideki Taniguchi
Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with a poor prognosis. It contains a complex tumor microenvironment (TME) that includes various stromal cell types. Comprehending cellular communications within the TME is difficult due to a lack of research models that can recapitulate human PDAC-TME. Previously, we recapitulated, in part, the PDAC-TME containing a diversity of cancer-associated fibroblasts (CAFs) in vitro. This was done by establishing a PDAC organoid by co-culturing patient-derived cancer cells with human induced pluripotent stem cell (hiPSC)-derived mesenchymal and endothelial cells, which was designated the fused pancreatic cancer organoid (FPCO). We further incorporated macrophages derived from the THP-1 cell line, which are the source of tumor-associated macrophages (TAMs), a major TME component, into FPCO, which was designated M0-FPCO. Bulk RNA sequencing (RNAseq) analysis revealed that macrophages in M0-FPCO (FPCO-Mac) lost their pro-inflammatory features but acquired pro-angiogenic features. Consistently, the formation of an endothelial cell network was enhanced in M0-FPCO. Single-cell RNA-seq (scRNA-seq) analysis revealed that M0-FPCO contained five TAM subpopulations similar to the corresponding TAM in human PDAC tissue in the integrated analysis, including SPP1+-TAM, which has been correlated with tumor angiogenesis and cell proliferation. Focusing on PDAC cells, we found that they could survive longer within the organoid in the presence of TAM. Consistent with the prolonged proliferation and survival of PDAC cells, PDAC subclusters were characterized by proliferative features, such as increased M0-FPCO. Therefore, by establishing a PDAC organoid with macrophages, we recapitulated the diversity of TAMs and identified the role of TAM in endothelial network formation as well as in the modulation of PDAC cell properties. SIGNIFICANCE: PDAC organoids, including macrophages using hiPSC, showed that PDAC-TAM has angiogenic features and contributes to PDAC cell survival.

9 June 2024 in Regenerative Therapy
Verified
Journal Article
Open access
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
NTNaoki Tanimizu
Naoki Tanimizu
Liver is involved in metabolic reactions, ammonia detoxification, and immunity. Multicellular liver tissue cultures are more desirable for drug screening, disease modeling, and researching transplantation therapy, than hepatocytes monocultures. Hepatocytes monocultures are not stable for long. Further, hepatocyte-like cells induced from pluripotent stem cells and in vivo hepatocytes are functionally dissimilar. Organoid technology circumvents these issues by generating functional ex vivo liver tissue from intrinsic liver progenitor cells and extrinsic stem cells, including pluripotent stem cells. To function as in vivo liver tissue, the liver organoid cells must be arranged precisely in the 3 -dimensional space, closely mimicking in vivo liver tissue. Moreover, for long term functioning, liver organoids must be appropriately vascularized and in contact with neighboring epithelial tissues (e.g., bile canaliculi and intrahepatic bile duct, or intrahepatic and extrahepatic bile ducts). Recent discoveries in liver developmental biology allows one to successfully induce liver component cells and generate organoids. Thus, here, in this review, we summarize the current state of knowledge on liver development with a focus on its application in generating different liver organoids. We also cover the future prospects in creating (functionally and structurally) in vivo-like liver organoids using the current knowledge on liver development. (c) 2024, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/

10 March 2026 in Genetics
Verified
Journal Article
Closed access
RMRyo Matsumoto
Ryo Matsumoto
HKHiroshi Kanda
Hiroshi Kanda
AKAya Kawasaki
Aya Kawasaki
MNMai Nakamura
Mai Nakamura
RNRina Nagata
Rina Nagata
TITatsushi Igaki
Tatsushi Igaki
Genetic studies in Drosophila have uncovered diverse molecules that drive cell competition, a quality control mechanism whereby less-fit cells are eliminated through interactions with fitter neighboring cells. This has raised the fundamental question of whether cell competition converges on shared molecular pathways, despite being initiated by distinct genetic alterations. To address this, we conducted a large-scale genetic screen in Drosophila across ∼12,500 mutant chromosomes and isolated 63 mutations that convert cells into losers of cell competition. Subsequent genetic analyses revealed that the vast majority of these “loser” mutations induce cell competition through one of two mechanisms: the bZip transcription factor Xrp1 or the Eiger/TNF-JNK signaling pathway. Genomic analyses further identified sets of genes required for nucleocytoplasmic mRNA export and septate junction function, but not cell polarity, as responsible genes for Xrp1- and Eiger/TNF-mediated cell competition, respectively. Our findings support the view that cell competition acts as a surveillance system that detects specific cellular malfunctions and eliminates defective cells via one of two core pathways mediated by Xrp1 or Eiger/TNF.

12 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YYYuya Yamamoto
Yuya Yamamoto
KTKenta Takeuchi
Kenta Takeuchi
STShunsuke Tabe
Shunsuke Tabe
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
HTHideki Taniguchi
Hideki Taniguchi
Summary: The specific contribution of tissue-resident macrophages (TRMs) to pancreatic ductal adenocarcinoma (PDAC) progression remains unclear. Here, we found that a high abundance of TRM-derived tumor-associated macrophages (TRM-TAMs) is an independent indicator of poor prognosis in patients with PDAC. To elucidate the underlying mechanism, we established an advanced organoid platform (iMac-FPCO), which incorporates macrophages derived from human induced pluripotent stem cells to reflect the differentiation process of TRMs. Single-cell transcriptomic analysis revealed this model recapitulates the transcriptional identity of TRM-TAMs in patient tissue. We demonstrated that TRM-TAMs drive cancer cell proliferation, while maintaining chemoresistance, and identified TRM-derived insulin-like growth factor 1 (IGF1) as the critical mediator. This result provides a rationale for why previous trials targeting IGF1 receptor (IGF1R) failed to improve survival in unselected patient populations. We hypothesize that stratifying patients by TRM-TAM abundance could help identify a responsive subgroup, thereby reviving IGF1R-targeted therapy as a viable treatment for PDAC.